Dr. Jorge De Alba is a respiratory pharmacologist by background with 20 years of experience in drug discovery in academia and the pharmaceutical industry. Jorge started his career at GSK as a postdoctoral research scientist and subsequently joined the Respiratory Pharmacology group in the National Heart and Lung institute as part of the Academic Alternative Drug Initiative in collaboration with GSK. During this time, Jorge led the research programme investigating the role of sensory nerves and neuroinflammation in the Late Asthmatic Response. Jorge then joined Almirall where he set up and led the respiratory pharmacology group and was instrumental in developing the Company’s PK/PD animal models of respiratory disease, which delivered several clinical candidates. At Almirall, Jorge successfully led and managed several collaborative projects and was Almirall’s representative in the UBIOPRED, a prestigious international severe asthma consortium within the Innovative Medicine Initiative of the European Union. Following his time at Almirall, Jorge joined Evotec as VP of Anti-infectives leading the in vivo pharmacology operations and contributed to Evotec’s global strategy as a member of the in vivo pharmacology leadership team.